Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow XENE by emailGet an email when XENE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about XENE, unsubscribe in one click. Privacy
📣 What XENE Says Is Next
in 2026 · “X-TOLE3 enrollment outside of Japan is expected to complete in 2026.”
Company press release, Aug 6, 2026 · SEC filing
first half of 2027 · ““We also remain focused on broadening azetukalner’s opportunity to neuropsychiatry and expect topline Phase 3 X-NOVA2 data in the first half of 2027.”
Company press release, Aug 6, 2026 · SEC filing
H2 2026 · “Phase 1 studies of novel Na V 1.7 (XEN1701) and K V 7 (XEN1120) candidates expected to complete H2 2026; Phase 1 study underway for second Na V 1.7 (XEN1720) candidate for pain”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full XENE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XENE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.